Initial Treatment Approach for Depression Unspecified
For a patient with DSM diagnosis of depression unspecified, initiate either cognitive behavioral therapy (CBT) or a second-generation antidepressant (SSRI or SNRI) as first-line treatment, with the choice guided by depression severity assessment, patient preference, and adverse effect profiles. 1, 2, 3
Immediate Assessment Requirements
Before initiating treatment, you must clarify the diagnosis and severity:
Confirm diagnostic criteria: Establish whether the patient meets full criteria for Major Depressive Disorder (at least 5 symptoms present during a 2-week period, with at least one being depressed mood or anhedonia, causing functional impairment). 2, 3, 4
Quantify baseline severity: Use the Patient Health Questionnaire-9 (PHQ-9) or Hamilton Depression Rating Scale (HAM-D) to establish severity classification (mild, moderate, or severe) based on symptom count, intensity, and degree of functional impairment. 2, 3, 4
Screen for critical exclusions: Assess for suicidality, bipolar disorder risk, psychotic symptoms, substance use, and co-occurring anxiety disorders before initiating treatment. 5
Treatment Selection Algorithm Based on Severity
For Mild Depression
Start with CBT alone as first-line treatment, as it demonstrates equivalent effectiveness to antidepressants with moderate-quality evidence and avoids medication-related adverse effects. 1, 2, 3
Antidepressants should NOT be used for initial treatment of mild depression, as drug-placebo differences are virtually nonexistent in this population. 1
For Moderate to Severe Depression
Initiate either CBT or second-generation antidepressants (SSRIs such as fluoxetine, or SNRIs), selected based on adverse effect profiles, cost, and patient preferences. 1, 2, 3, 5
Consider combination therapy (psychotherapy plus antidepressant) for more severe or chronic presentations, as combined treatment shows greater symptom improvement than either modality alone (standardized mean difference 0.30-0.33). 5
Specific psychotherapy options with demonstrated efficacy include cognitive therapy, behavioral activation, problem-solving therapy, interpersonal therapy, brief psychodynamic therapy, and mindfulness-based psychotherapy. 5
Treatment Monitoring Protocol
Assess response within 1-2 weeks of treatment initiation, monitoring specifically for therapeutic effects, adverse effects, and emergence of suicidality. 2, 3, 4
Evaluate for adequate response by 6-8 weeks: If inadequate improvement, modify treatment through dose adjustment, switching agents, or adding augmentation strategies. 2
Continue treatment for 4-9 months after satisfactory response for first episodes; extend to ≥1 year for recurrent episodes to prevent relapse. 2, 3, 4
Critical Pitfalls to Avoid
Do not prescribe antidepressants for depressive symptoms without confirmed moderate or severe depressive episode/disorder, as this represents inappropriate treatment with no demonstrated benefit. 1
Avoid premature discontinuation before therapeutic effects are achieved (typically 4-6 weeks minimum for antidepressants). 2
Do not use tricyclic antidepressants as first-line agents in non-specialist settings; SSRIs or SNRIs are preferred due to better tolerability and safety profiles. 2
Never initiate treatment without establishing baseline severity measurement using validated tools, as severity classification directly determines appropriate treatment selection. 2, 3
Special Considerations
The most reliable evidence for similar treatment benefits to antidepressants comes from CBT and St. John's wort, both demonstrating lower risks for discontinuation due to adverse events compared to antidepressants. 1 However, the choice between nonpharmacologic and pharmacologic approaches should follow a discussion about advantages, disadvantages, previous treatment experiences, and patient preferences. 1
For patients who fail to respond adequately to initial antidepressant treatment, switching to another antidepressant, switching to cognitive therapy, or augmenting with specific medications or cognitive therapy are all reasonable second-step options with approximately equal likelihood of success. 1